Coreg CR Related Published Studies
Well-designed clinical trials related to Coreg CR (Carvedilol)
Nifedipine versus carvedilol in the treatment of de novo arterial hypertension after liver transplantation: results of a controlled clinical trial. [2008.07]
Comparison of the efficacy of metoprolol and carvedilol for preventing atrial fibrillation after coronary bypass surgery. [2008.05.07]
Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure. [2008.04]
Comparison of the effects of carvedilol and metoprolol on exercise ventilatory efficiency in patients with congestive heart failure. [2008.03]
Safety and efficacy of carvedilol therapy for patients with dilated cardiomyopathy secondary to muscular dystrophy. [2008.03]
The impact of carvedilol on the defibrillation threshold. [2008.01]
Comparative dose titration responses to the introduction of bisoprolol or carvedilol in stable chronic systolic heart failure. [2007.12]
Carvedilol in dogs with dilated cardiomyopathy. [2007.11]
Ethanol does not alter the pharmacokinetic profile of the controlled-release formulation of carvedilol. [2007.11]
Effect of carvedilol and metoprolol on the mode of death in patients with heart failure. [2007.11]
Effects of carvedilol early after myocardial infarction: analysis of the first 30 days in Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN). [2007.10]
Effect of beta-blocker therapy on left atrial function in patients with heart failure: comparison of metoprolol succinate with carvedilol. [2007.10]
Carvedilol for children and adolescents with heart failure: a randomized controlled trial. [2007.09.12]
Optimal beta-blocker for prevention of atrial fibrillation after on-pump coronary artery bypass graft surgery: carvedilol versus metoprolol. [2007.09]
Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). [2007.08]
Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial. [2007.08]
Lung function with carvedilol and bisoprolol in chronic heart failure: is beta selectivity relevant? [2007.08]
Randomized active-controlled study comparing effects of treatment with carvedilol versus metoprolol in patients with left ventricular dysfunction after acute myocardial infarction. [2007.07]
Effects of long-term treatment with carvedilol on myocardial blood flow in idiopathic dilated cardiomyopathy. [2007.07]
Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus. [2007.07]
Exercise training reduces sympathetic nerve activity in heart failure patients treated with carvedilol. [2007.06]
Achiral-chiral LC/LC-FLD coupling for determination of carvedilol in plasma samples for bioequivalence purposes. [2007.05.01]
Carvedilol Reduces Elevated B-type Natriuretic Peptide in Dialyzed Patients Without Heart Failure: Cardioprotective Effect of the beta-blocker. [2007.04]
A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy. [2007.04]
Evaluation of cardiac sympathetic nerve activity and left ventricular remodelling in patients with dilated cardiomyopathy on the treatment containing carvedilol. [2007.04]
Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. [2007.03.06]
Beneficial effects of carvedilol as a concomitant therapy to angiotensin-converting enzyme inhibitor in patients with ischemic left ventricular systolic dysfunction. [2007.02]
The antioxidative effects of long-term treatment are more pronounced for carvedilol than for atenolol in post-myocardial infarction patients. [2007.01]
Carvedilol in the treatment of chronic heart failure: lessons from the Carvedilol Or Metoprolol European Trial. [2007]
Protective effects of carvedilol against anthracycline-induced cardiomyopathy. [2006.12.05]
Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension. [2006.12]
Adrenergic blocker carvedilol attenuates the cardiovascular and aversive effects of nicotine in abstinent smokers. [2006.12]
Carvedilol reduces exercise-induced hyperventilation: A benefit in normoxia and a problem with hypoxia. [2006.11]
[The effectiveness of carvedilol in heart failure] [2006.10.08]
Controlled-release carvedilol in the treatment of essential hypertension. [2006.10.02]
Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension. [2006.10.02]
Randomized, double-blind comparison of acute beta1-blockade with 50 mg metoprolol tartrate vs 25 mg carvedilol in normal subjects. [2006.09]
Carvedilol versus Metoprolol for the prevention of atrial fibrillation after off-pump coronary bypass surgery: rationale and design of the Carvedilol or Metoprolol Post-Revascularization Atrial Fibrillation Controlled Trial (COMPACT). [2006.06]
The effect of carvedilol on metabolic parameters in patients with metabolic syndrome. [2006.05]
A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET). [2006.04.18]
Rapid titration of carvedilol in patients with congestive heart failure: a randomized trial of automated telemedicine versus frequent outpatient clinic visits. [2006.04]
After myocardial infarction carvedilol improves insulin resistance compared to metoprolol. [2006.02]
The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis. [2006.02]
Randomized placebo-controlled study on the effects of losartan and carvedilol on albuminuria in renal transplant recipients. [2006.01.15]
Comparison of carvedilol and metoprolol in patients with acute myocardial infarction undergoing primary coronary intervention--the PASSAT Study. [2006.01]
Effects of nebivolol versus carvedilol on left ventricular function in patients with chronic heart failure and reduced left ventricular systolic function. [2006]
Comparing beta-blocking effects of bisoprolol, carvedilol and nebivolol. [2006]
Carvedilol exerts more potent antiadrenergic effect than metoprolol in heart failure. [2005.10]
Different responses to dobutamine in the presence of carvedilol or metoprolol in patients with chronic heart failure. [2003.06]
Well-designed clinical trials possibly related to Coreg CR (Carvedilol)
Inpatient initiation of beta-blockade plus nurse management in vulnerable heart failure patients: a randomized study. [2008.05]
A Review of Evidence-Based beta-Blockers in Special Populations With Heart Failure. [2008.03]
Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure. [2008.01]
Pediatric Heart Failure Therapy with beta-Adrenoceptor Antagonists. [2008]
Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial. [2007.11]
Cardiovascular disease in patients with chronic kidney disease. A clinical review. [2007.09]
The effects of beta-blockers in patients with stable chronic heart failure. Predictors of left ventricular ejection fraction improvement and impact on prognosis. [2007.09]
Does NT-proBNP remain a sensitive biomarker for chronic heart failure after administration of a beta-blocker? [2007.09]
Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET. [2007.09]
Body weight changes with beta-blocker use: results from GEMINI. [2007.07]
Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI. [2007.07]
Clinical reminders attached to echocardiography reports of patients with reduced left ventricular ejection fraction increase use of beta-blockers: a randomized trial. [2007.06.05]
Effects of beta-blocker therapy on high sensitivity c-reactive protein, oxidative stress, and cardiac function in patients with congestive heart failure. [2007.06]
The safety of amiodarone in patients with heart failure. [2007.06]
beta-blocker use and diabetes symptom score: results from the GEMINI study. [2007.05]
Modification of cardiovascular risk in hemodialysis patients: An evidence-based review. [2007.01]
Renal allograft protection with angiotensin II type 1 receptor antagonists. [2007.01]
Effects of monotherapy and combination therapy on blood pressure control and target organ damage: a randomized prospective intervention study in a large population of hypertensive patients. [2006.09]
Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy. [2006.08]
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. [2006.07.11]
The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. [2006.06]
The effects of combined versus selective adrenergic blockade on left ventricular and systemic hemodynamics, myocardial substrate preference, and regional perfusion in conscious dogs with dilated cardiomyopathy. [2006.05.02]
[Chronic heart failure treatment in uremic patients with beta-blockers] [2006.05]
[Future perspectives of beta-blockers in chronic heart failure] [2006.05]
The use of metoprolol CR/XL in the treatment of patients with diabetes and chronic heart failure. [2006]
Do beta-blockers prolong survival in heart failure only by inhibiting the beta1-receptor? A perspective on the results of the COMET trial. [2003.12]
Other research related to Coreg CR (Carvedilol)
Carvedilol versus controlled-release metoprolol for elderly veterans with heart failure. [2008.06]
The influence of carvedilol on atrial connexin 40 after myocardial infarction. [2008.06]
Appropriate dose transition to a controlled-release formulation of carvedilol in patients with hypertension. [2008.03]
Population pharmacokinetics of S(-)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemate. [2007.06.15]
Carvedilol improves left atrial and left ventricular function and reserve in dilated cardiomyopathy after 1 year of treatment. [2007.03]
Rationale and design of CASPER: compliance and quality of life study comparing once-daily carvedilol CR and twice-daily carvedilol IR in patients with heart failure. [2006.10.02]
COMPARE: Comparison of the Effects of Carvedilol CR and Carvedilol IR on Left Ventricular Ejection Fraction in Patients with Heart Failure. [2006.10.02]
Cardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile. [2006.10.02]
Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction. [2006.10.02]
Development of a pharmacokinetic/pharmacodynamic model for carvedilol to predict beta1-blockade in patients with congestive heart failure. [2006.10.02]
The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. [2001]
Other possibly related research studies
Use of beta-blockers in congestive heart failure. [2003]
Beta-blockers in heart failure. The 'new wave' of clinical trials. [1999.08]
Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. [2008.05.27]
Beta-blockers have a beneficial effect upon endothelial function and microalbuminuria in African-American subjects with diabetes and hypertension. [2008.04.15]
Beta-blockers have a beneficial effect upon endothelial function and microalbuminuria in African-American subjects with diabetes and hypertension. [2008.09]
|
